HC Wainwright Boosts Earnings Estimates for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS) – Analysts at HC Wainwright boosted their FY2024 EPS estimates for Gossamer Bio in a research note issued to investors on Monday, November 11th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.18) per share for the year, up from their previous forecast of ($0.21). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q4 2024 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($0.18) EPS, FY2027 earnings at ($0.01) EPS and FY2028 earnings at $0.28 EPS.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. The company had revenue of $9.48 million during the quarter, compared to analysts’ expectations of $4.52 million.

Separately, Wedbush reaffirmed an “outperform” rating and issued a $4.00 price objective on shares of Gossamer Bio in a research report on Tuesday, August 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $9.20.

Gossamer Bio Stock Down 1.2 %

Shares of NASDAQ:GOSS opened at $0.85 on Wednesday. The business’s 50-day simple moving average is $0.94 and its 200 day simple moving average is $0.86. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. Gossamer Bio has a one year low of $0.50 and a one year high of $1.60.

Institutional Investors Weigh In On Gossamer Bio

Several hedge funds and other institutional investors have recently bought and sold shares of GOSS. SG Americas Securities LLC acquired a new stake in shares of Gossamer Bio during the first quarter worth approximately $34,000. US Bancorp DE bought a new position in Gossamer Bio during the 3rd quarter valued at $39,000. Choreo LLC acquired a new position in Gossamer Bio during the 2nd quarter worth $46,000. GSA Capital Partners LLP bought a new stake in shares of Gossamer Bio in the 3rd quarter worth about $67,000. Finally, Algert Global LLC acquired a new stake in shares of Gossamer Bio in the 2nd quarter valued at about $75,000. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.